In this narrative review, we aim to identify the challenges of reaching and maintaining body weight targets in people with type 2 diabetes and highlight current and future treatment interventions including high‐dose glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA that may enable simultaneous achievement of individual glycemic and weight goals. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.